Genomic medicine developer Precision Biosciences plans to raise up to $100m in an upcoming IPO that could hand exits to Duke University and corporates Amgen, EMS and Baxter.
Precision BioSciences, a US-based genomic medicine spinout of Duke University, has filed to raise up to $100m in an initial public offering.
The company plans to float on the Nasdaq Global Market and has appointed JP Morgan, Goldman Sachs, Jefferies and Barclays as joint bookrunners for the IPO.
Founded in 2006, Precision BioSciences has created a genome editing platform dubbed Arcus, which is being used in the development of immuno-oncology and genetic disease treatments, as well as…
